Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
Actuate Therapeutics, Inc. has priced an underwritten public offering of its securities to raise $11.0 million in gross proceeds.
Stocks · News reference
Filed: 2026-10-28 AccNo: 0001683168-26-008143 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Actuate Therapeutics, Inc. has priced an underwritten public offering of its securities to raise $11.0 million in gross proceeds.
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.